Cefuroxime Axetil tablets USP 250 and 500mg

Cefuroxime axetil tablets contain cefuroxime as cefuroxime axetil. Cefuroxime axetil is a semisynthetic, broad-spectrum cephalosporin antibiotic for oral administration.

Therapeutic Indications

Cefuroxime axetil is indicated for the treatment of mild to moderately severe infections caused by micro-organism susceptible cefuroxime, such as:

  • Upper respiratory tract infection: acute, sinusitis, tonsillitis and pharyngitis
  • Acute bronchitis, acute exacerbations of chronic bronchitis
  • Lower uncomplicated urinary tract infection: cystitis
  • Skin and soft tissue infections: furunculosis, pyodermas, and impetigo
  • Treatment of early-stage Lyme disease (stadium 1) and subsequent prevention of late complications in adults and children above 12 years of age.                                                                                                                           Consideration should be given to official guidance on the appropriate use of antibacterial agents.Posology and Method of AdministrationCefuroxime axetil tablets are coated to mask their taste: they should not be chewed.

    The usual duration of therapy is 7 days (ranging from 5 to 10 days). In case of pharyngotonsillitis caused by Streptococcus pyogenes, a therapy duration of at least 10 days is indicated. The duration of treatment of early Lyme disease should be 20 days. In order to achieve optimum absorption cefuroxime, axetil tablets should be taken shortly after meals.

    The dosage depends on the severity of the infection. For severe infections, parenteral forms of cefuroxime are recommended. Where appropriate cefuroxime axetil is effective when used following initial parenteral cefuroxime sodium in the treatment of pneumonia and acute exacerbations of chronic bronchitis


Clinical Pharmacology

The in vivo bactericidal activity of cefuroxime axetil is due to cefuroxime’s binding to essential target proteins and the resultant inhibition of cells-well synthesis.
Cefuroxime has bactericidal activity against a wide range of common pathogens, including many beta-lactamase-producing strains.
Cefuroxime is stable to may bacterial beta-lactamases, especially plasmid-mediated enzymes that are commonly found in Enterobacteriaceae.
Cefuroxime has been demonstrated to be active against most strains of the following microorganisms both in Vitro and in clinical infections as described.

Products Profile

Download Products Profile


Other Info

Absorption: After oral administration of cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed in the intestinal mucosa and body causing the release of the active compound of cefuroxime into the circulation. Optimum absorption occurs when cefuroxime is taken shortly after a meal (50-60%). Under these circumstances, maximum serum concentration is achieved after 2-3 hours.
Distribution: Cefuroxime is widely distributed in the body including pleural fluid, sputum, bone, synovial fluid, and aqueous humor, but only achieves therapeutic concentrations in the CSF when the meninges are inflamed. About 50% of cefuroxime in the circulations is bound to plasma proteins. It diffuses across the placenta and has been deleted in break milk.
Metabolism: cefuroxime is not metabolized.
Elimination: Most of the dose of cefuroxime is excreted unchanged. About 50% is excreted by glomerular filtration and about 50% through renal tubular secretion within 24 hours, with the majority being eliminated within 6 hours; high concentrations are achieved in the urine. Small amounts of cefuroxime are excreted in bile.
Probenecid competes with cefuroxime for renal tubular secretion resulting in higher and more prolonged plasma concentrations of cefuroxime.